
The Holy Grail Hunt in De Novo Antibody Design
Monoclonal antibodies (mAbs) have become a prominent therapeutic modality due to their binding specificity and ability to engage a diverse range of targets. However, isolating mAbs remains a laborious process, traditionally requiring animal immunization or vast library screens of randomly generated variants. To address these limitations, a research team at the University of Washington, led…